Guardant Health (GH) announced that real-world evidence generated from Guardant’s InfinityAI contributed to the recent approval of ENHERTU, developed and commercialized by Daiichi Sankyo in Japan, for the treatment of patients with HER2-positive advanced or recurrent solid cancers refractory or intolerant to standard treatments. This approval, granted by Japan’s Ministry of Health, Labour and Welfare, MHLW, was supported by data from the HERALD, DESTINY-PanTumor02, DESTINY-CRC02 and DESTINY-Lung01 clinical trials and supplemental real-world evidence, RWE, generated using the real-world data platform from InfinityAI, Guardant Health’s artificial intelligence platform.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health, Verana Health announce new partnership
- Insiders Shake Up Guardant, Ovintiv, Redwire, Builders FirstSource, Permian
- Guardant Health price target raised to $130 from $120 at Piper Sandler
- Guardant Health price target raised to $129 from $115 at Raymond James
- Guardant Health Earnings Call Highlights Growth And Burn